Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies

Inclusion Criteria: * Adults aged 18 to \<70 years, any gender. * Voluntarily provide written informed consent and willing to comply with all study procedures. * Diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL), or other relapsed/refractory hematologic malignancies as judged by the investigator and confirmed by the collaborating institution. * Tumor cells confirmed positive for the target antigen by immunophenotyping. * Bone marrow blast ≥5% at screening and/or presence of extramedullary disease. * For B-ALL/LBL patients, meets criteria for relapsed/refractory disease, including: * Primary refractory after ≥2 cycles of standard chemotherapy or not achieving CR after multiple salvage regimens; * Relapse within 12 months after CR or ≥12 months relapse after CR not achieving CR after subsequent standard therapy; * Relapse after hematopoietic stem cell transplantation; * Relapse after prior CAR-T therapy targeting the same antigen. * ECOG performance status 0-2. * Expected survival \>3 months. * Adequate organ function, including: * Renal: creatinine clearance \>45 mL/min; * Hepatic: total bilirubin ≤3×ULN, ALT/AST ≤5×ULN; * Coagulation: PT, APTT, or INR ≤1.5×ULN; * Cardiac: LVEF ≥50% within 1 month; * Pulmonary: SpO₂ ≥92% at rest on room air; * Hematologic and immune function considered sufficient to tolerate study treatment. * Women of childbearing potential must have a negative pregnancy test; women considered not of childbearing potential include those who are postmenopausal for ≥12 months or have undergone surgical sterilization (hysterectomy or bilateral oophorectomy). Exclusion Criteria: * Pregnant or breastfeeding women. * Known hereditary bone marrow failure syndromes (e.g., Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other known marrow failure syndromes). * Uncontrolled active central nervous system leukemia (CNSL; CNS2 or CNS3). * Prior anti-cancer therapy before screening, including: * Systemic chemotherapy within 1 week; * Systemic immunotherapy/targeted therapy (monoclonal antibodies, bispecific antibodies, ADCs, etc.) with last dose \<5 half-lives or \<4 weeks (whichever is shorter); * Donor lymphocyte infusion within 6 weeks; * CAR-T therapy or hematopoietic stem cell transplantation within 3 months; * Radiotherapy within 4 weeks (unless bone marrow reserve \>5% and investigator judges it does not affect eligibility); * Persistent clinically significant toxicity from prior therapy not recovered to ≤CTCAE Grade 1 (except alopecia). * Uncontrolled severe active infection. * History of significant cardiac disease, including: severe heart failure (NYHA class III-IV), myocardial infarction or PCI/stent within 12 months, unstable angina, QTc \>480 ms, or other clinically significant arrhythmia per investigator judgment. * History of CNS injury, seizure, stroke, or brain hemorrhage requiring treatment within 6 months. * Active viral infections: * HIV antibody positive, syphilis serology positive; * HBsAg \>10⁶ IU/mL; * HCV antibody positive; * EBV positive (EBER or copy number above normal). * Need for long-term systemic corticosteroid therapy during DIT-101 infusion (local or inhaled steroids allowed). * Active autoimmune disease requiring treatment, immunodeficiency, or use of immunosuppressive therapy. * Acute or moderate-to-severe chronic graft-versus-host disease (GvHD) within 4 weeks prior to screening. * Known severe allergy to any component of DIT-101. * Women of childbearing potential or men unable to use effective contraception during DIT-101 infusion and for 1 year post-infusion; plans for pregnancy within 1 year post-infusion in male or female subjects or their partners. * Any condition that, in the investigator's opinion, may increase risk or interfere with study outcomes. * Prior malignancy other than hematologic malignancy, except: * Malignancy treated with curative intent and disease-free ≥2 years; * Non-melanoma skin cancer adequately treated with no current evidence of disease.